Your browser doesn't support javascript.
loading
Side Effects from Cancer Therapies and Perspective of 1044 Long-Term Ovarian Cancer Survivors-Results of Expression VI-Carolin Meets HANNA-Holistic Analysis of Long-Term Survival with Ovarian Cancer: The International NOGGO, ENGOT, and GCIG Survey.
Woopen, Hannah; Keller, Maren; Zocholl, Dario; Mittelstadt, Suzana; Barretina-Ginesta, Maria-Pilar; Heinzelmann-Schwarz, Viola; Lafleur, Judith; Kocián, Roman; Baum, Joanna; Krabisch, Petra; Achimas-Cadariu, Patriciu; Vardar, Mehmet Ali; Vergote, Ignace; Nasser, Sara; Link, Theresa; Gil-Martin, Marta; Zwimpfer, Tibor A; Leitner, Katharina; Jedryka, Marcin; Boxler, Tamara; Braicu, Elena Ioana; Sehouli, Jalid.
Afiliación
  • Woopen H; Department of Gynecology with Center for Oncological Surgery, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.
  • Keller M; North-Eastern German Society for Gynecological Oncology (NOGGO), 13359 Berlin, Germany.
  • Zocholl D; North-Eastern German Society for Gynecological Oncology (NOGGO), 13359 Berlin, Germany.
  • Mittelstadt S; North-Eastern German Society for Gynecological Oncology (NOGGO), 13359 Berlin, Germany.
  • Barretina-Ginesta MP; Institute of Biometry and Clinical Epidemiology, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.
  • Heinzelmann-Schwarz V; North-Eastern German Society for Gynecological Oncology (NOGGO), 13359 Berlin, Germany.
  • Lafleur J; Department of Women's Health, University Hospital Tübingen, 72076 Tübingen, Germany.
  • Kocián R; Institut Català d'Oncologia, Medical Oncology Department, 17007 Girona, Spain.
  • Baum J; Precision Oncology Group, Institut d'Investigació Biomèdica de Girona, 17007 Girona, Spain.
  • Krabisch P; Medical Sciences Department, Universitat de Girona, 17003 Girona, Spain.
  • Achimas-Cadariu P; Grupo Español de Investigación en Cáncer de Ovario (GEICO), 28003 Madrid, Spain.
  • Vardar MA; Department of Gynecology and Gynecologic Oncology, University Hospital of Basel, 4056 Basel, Switzerland.
  • Vergote I; Swiss GO Trial Group (Swiss-GO), 4031 Basel, Switzerland.
  • Nasser S; Department of Gynecology and Obstetrics, Ordensklinikum Barmherzige Schwestern Linz, 4020 Linz, Austria.
  • Link T; Arbeitsgemeinschaft Gynaekologische Onkologie Austria (AGO Austria), 6020 Innsbruck, Austria.
  • Gil-Martin M; Department of Gynaecology, Obstetrics and Neonatology First Faculty of Medicine, Charles University and General University Hospital in Prague, 12 108 Prague, Czech Republic.
  • Zwimpfer TA; General University Hospital in Prague, 12 808 Prague, Czech Republic.
  • Leitner K; Central and Eastern European Gynecologic Oncology Group (CEEGOG), 128 51 Prague, Czech Republic.
  • Jedryka M; Department of Gynecology with Center for Oncological Surgery, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.
  • Boxler T; North-Eastern German Society for Gynecological Oncology (NOGGO), 13359 Berlin, Germany.
  • Braicu EI; North-Eastern German Society for Gynecological Oncology (NOGGO), 13359 Berlin, Germany.
  • Sehouli J; Department of Gynaecology and Obstetrics, Klinikum Chemnitz, 09116 Chemnitz, Germany.
Cancers (Basel) ; 15(22)2023 Nov 15.
Article en En | MEDLINE | ID: mdl-38001688
ABSTRACT
The aim of this survey was to increase the knowledge on the characteristics and health concerns of long-term survivors (LTS; survival > 5 years) after ovarian cancer in order to tailor follow-up care. This international survey was initiated by the NOGGO and was made available to members of ENGOT and GCIG. The survey is anonymous and consists of 68 questions regarding sociodemographic, medical (cancer) history, health concerns including distress, long-term side effects, and lifestyle. For this analysis, 1044 LTS from 14 countries were recruited. In total, 58% were diagnosed with FIGO stage III/IV ovarian cancer and 43.4% developed recurrent disease, while 26.0% were receiving cancer treatment at the time of filling in the survey. LTS who survived 5-10 years self-estimated their health status as being significantly worse than LTS who survived more than 10 years (p = 0.034), whereas distress also remained high 10 years after cancer diagnosis. Almost half of the cohort (46.1%) reported still having symptoms, which were mainly lymphedema (37.7%), fatigue (23.9%), pain (21.6%), polyneuropathy (16.9%), gastrointestinal problems (16.6%), and memory problems (15.5%). Almost all patients (94.2%) regularly received follow-up care. Specialized survivorship care with a focus on long-term side effects, lifestyle, and prevention should be offered beyond the typical five years of follow-up care.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Alemania